Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Inflammatory Bowel Diseases

Free Subscription 29.06.2026 2 Aliment Pharmacol Ther 2 BMC Gastroenterol 2 Clin Gastroenterol Hepatol 2 Dig Dis Sci 3 Eur J Gastroenterol Hepatol 4 Gastroenterology 5 Inflamm Bowel Dis 4 J Crohns Colitis 1 J Gastroenterol 1 J Immunol 1 Mediators Inflamm 1 PLoS One 2 Z Gastroenterol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Aliment Pharmacol Ther

1. TANG CZ, Faye AS
   Letter: Does the Association Between Mild Endoscopic Activity and Adverse Outcomes Justify Treatment Escalation in Older Adults With Inflammatory Bowel Disease? Authors' Reply.
   Aliment Pharmacol Ther. 2026 Jun 22. doi: 10.1111/apt.70822.
   PubMed        
   
   
2. RICHARD N, Fumery M
   Editorial: Upadacitinib in Perianal Crohn's Disease. Authors' Reply.
   Aliment Pharmacol Ther. 2026 Jun 20. doi: 10.1111/apt.70817.
   PubMed        
   
   

   
   BMC Gastroenterol

3. UPADHYAY N, Ketkar A, Mert C, Wallem A, et al
   Real-world outcomes of tumour necrosis factor inhibitor (TNFi) cyclers versus mechanism-of-action switchers among ulcerative colitis patients who failed first-line TNFi.
   BMC Gastroenterol. 2026 Jun 20. doi: 10.1186/s12876-026-04829.
   PubMed         Abstract available
   
   
4. TIAN Z, Xiang Q, Long M, Liao J, et al
   Chemerin as a biomarker of inflammatory bowel diseases: a meta-analysis.
   BMC Gastroenterol. 2025;25:662.
   PubMed         Abstract available
   
   

   
   Clin Gastroenterol Hepatol

5. FARKAS B, Resal T, Lakatos PL, Bessissow T, et al
   Upadacitinib Is Associated With Better Clinical and Biochemical Outcomes Than Tofacitinib in Refractory, Moderate-to-Severe Ulcerative Colitis.
   Clin Gastroenterol Hepatol. 2026;24:1950-1959.
   PubMed         Abstract available
   
   
6. HALIM A, Ho AHY, Wanchaitanawong W, Ng SC, et al
   Phenotypic Differences in Inflammatory Bowel Diseases Across Race, Ethnicity, and Geography: A Systematic Review of 237 Population-Based Studies.
   Clin Gastroenterol Hepatol. 2026;24:1790-1799.
   PubMed         Abstract available
   
   

   
   Dig Dis Sci

7. HERRAN R, Wilcox S, Hodish G, Hassan SA, et al
   Navigating Treatment Selection in Acute Severe Ulcerative Colitis: A Prospective Mixed Method Analysis of Factors Influencing Patient Decision-Making.
   Dig Dis Sci. 2026 Jun 24. doi: 10.1007/s10620-026-10046.
   PubMed         Abstract available
   
   
8. VAN OUYTSEL P, Cremer A, Franchimont D, Liefferinckx C, et al
   Screening of Avoidance/Restrictive Food Intake Disorder (ARFID) in Patients with Quiescent Inflammatory Bowel Disease and Irritable Bowel Syndrome-Like Symptoms.
   Dig Dis Sci. 2026 Jun 22. doi: 10.1007/s10620-026-10067.
   PubMed         Abstract available
   
   

   
   Eur J Gastroenterol Hepatol

9. SUBEDI A, Chaar A, Suhail FK, Hussain A, et al
   Indirect comparison of endoscopic balloon dilatation, stent placement, and stricturotomy for lower gastrointestinal strictures in Crohn's disease: a systematic review and meta-analysis.
   Eur J Gastroenterol Hepatol. 2026;38:933-940.
   PubMed         Abstract available
   
   
10. MIYAKE Y, Tanaka K, Nagata C, Furukawa S, et al
    Dietary B vitamin intake and risk of ulcerative colitis: a case-control study.
    Eur J Gastroenterol Hepatol. 2026 Jun 23. doi: 10.1097/MEG.0000000000003217.
    PubMed         Abstract available
    
    
11. TURSI A, Elisei W, Terlizzi AP, Antonino N, et al
    Impact of biosimilars on the costs of advanced therapies for inflammatory bowel diseases: a population-based study in Italy.
    Eur J Gastroenterol Hepatol. 2026;38:902-908.
    PubMed         Abstract available
    
    

    
    Gastroenterology

12. RUDBAEK JJ, Jess T, Ottosson F
    Reply to "Methodological Considerations on Neonatal Metabolomics and Future Inflammatory Bowel Disease".
    Gastroenterology. 2026 Jun 23:S0016-5085(26)06986.
    PubMed        
    
    
13. WANG Y
    Methodological Considerations on Neonatal Metabolomics and Future Inflammatory Bowel Disease.
    Gastroenterology. 2026 Jun 23:S0016-5085(26)06985.
    PubMed        
    
    
14. ROSENFELD G, Narula N, Leung Y, Afif W, et al
    Proactive Fecal Calprotectin Home Monitoring in Ulcerative Colitis: Results of a Prospective Randomized Control Trial.
    Gastroenterology. 2026 Jun 23:S0016-5085(26)06980.
    PubMed         Abstract available
    
    
15. LI Q, Nambu R, Yaqiang H, Shen X, et al
    BIRC3 (Encoding Cellular Inhibitor of Apoptosis Protein 2) Variants Result in Dysregulated Receptor-Interacting Protein Kinase 1 Signaling Leading to Increased Epithelial Cell Death and Are Associated With Monogenic Crohn's Disease.
    Gastroenterology. 2026 Jun 23:S0016-5085(26)06946.
    PubMed         Abstract available
    
    

    
    Inflamm Bowel Dis

16. MANCHERON A, Martinez-Vinson C, Beaugerie L, Pigneur B, et al
    Benefit-risk balance of advanced therapies in pediatric inflammatory bowel disease: evidence and gaps versus adults.
    Inflamm Bowel Dis. 2026 Jun 23:izag123. doi: 10.1093.
    PubMed         Abstract available
    
    
17. BAKHSHI Z, Kumari R, Devi J
    Imaging-based prediction of biologic failure in perianal Crohn's disease: the emerging role of 3D transrectal ultrasound.
    Inflamm Bowel Dis. 2026 Jun 22:izag125. doi: 10.1093.
    PubMed        
    
    
18. GUASCH M, Calafat M, Gargallo-Puyuelo CJ, De Francisco R, et al
    Clinical features and therapeutic requirements of perianal disease in adult patients with ulcerative colitis: the PERICO study of the ENEIDA registry.
    Inflamm Bowel Dis. 2026 Jun 21:izag120. doi: 10.1093.
    PubMed         Abstract available
    
    
19. MORAN GP, McQuillan A, Ho GT, Whelan RJ, et al
    Modified Crohn's Disease Exclusion Diet and exclusive enteral nutrition (EEN) resolve oral dysbiosis in pediatric Crohn's disease: a prospective cohort study.
    Inflamm Bowel Dis. 2026 Jun 20:izag107. doi: 10.1093.
    PubMed         Abstract available
    
    
20. KHAN N, Sundararajan R, Caldera F, Farraye FA, et al
    Respiratory syncytial virus incidence and clinical outcomes in patients with inflammatory bowel disease: a National Veterans Affairs cohort study.
    Inflamm Bowel Dis. 2026 Jun 23:izag103. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Crohns Colitis

21. GOODWIN SW, Yuan Y, Singh S, Solitano V, et al
    The impact of global recruitment and country income on placebo rates in inflammatory bowel disease clinical trials.
    J Crohns Colitis. 2026;20:jjag081.
    PubMed         Abstract available
    
    
22. BALMER C, Korgaard J, Holmboe CH, Neldeborg S, et al
    Limited placental transfer and clearance of risankizumab by 6 months following in utero exposure.
    J Crohns Colitis. 2026;20:jjag086.
    PubMed         Abstract available
    
    
23. FARKOUH A, Nathoo-Khedri N, Dufresne A, Danaie H, et al
    Clinical outcomes following switch from risankizumab to guselkumab in Crohn's disease: a real-world case series.
    J Crohns Colitis. 2026;20:jjag089.
    PubMed         Abstract available
    
    
24. VAN DEN BORREN S, Guadagnoli L, Teugels A, van den Eijnden I, et al
    Gastrointestinal symptom-specific anxiety is associated with disability in inflammatory bowel diseases independent of general anxiety and self-reported disease activity: evidence from a large cross-sectional patient study.
    J Crohns Colitis. 2026;20:jjag079.
    PubMed         Abstract available
    
    

    
    J Gastroenterol

25. PENG R, Lin L, Ye C
    Comment on: Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease.
    J Gastroenterol. 2026 Jun 19. doi: 10.1007/s00535-026-02466.
    PubMed        
    
    

    
    J Immunol

26. CHEN M, Melhem H, Niess JH
    Genetic deletion of the inflammatory bowel disease-associated risk gene Rgs14 aggravates experimental colitis.
    J Immunol. 2026;215:vkag135.
    PubMed         Abstract available
    
    

    
    Mediators Inflamm

27. LV X, Qi Y, Guo J, Ba L, et al
    REG3A: A Potential Fecal Biomarker for Ulcerative Colitis.
    Mediators Inflamm. 2026;2026:e9316792.
    PubMed         Abstract available
    
    

    
    PLoS One

28. GUNES AYDEMIR N, Oral AC, Tasar Yildirim T
    More than a digestive disorder: Perceived stigma in inflammatory bowel disease patients.
    PLoS One. 2026;21:e0352696.
    PubMed         Abstract available
    
    

    
    Z Gastroenterol

29. BLUMENSTEIN I, Dignass A, Kucharzik T, Schnoy E, et al
    [Version 7.0 of the S3 Guideline on Ulcerative Colitis sets out clearly defined treatment goals, an open treatment sequence, and a call for improved cross-sectoral care].
    Z Gastroenterol. 2026;64:665-666.
    PubMed        
    
    
30. BLUMENSTEIN I, Schnoy E, Atreya R, Bettenworth D, et al
    [Updated S3 guideline on ulcerative colitis].
    Z Gastroenterol. 2026;64:689-827.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum